89 results
8-K
EX-99.1
PHASQ
PhaseBio Pharmaceuticals Inc
12 Aug 21
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
10:11am
:
Current portion of long-term debt
Current portion of deferred sublicense revenue
Accounts payable, accrued expenses and other current liabilities
Long-term debt … , net
Operating lease liabilities, net
Deferred sublicense revenue, net
Development derivative liability
Other long-term liabilities
Stockholders
8-K
EX-99.1
PHASQ
PhaseBio Pharmaceuticals Inc
16 May 22
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
12:00am
-of-use assets
Other non-current assets
Total assets
Liabilities and stockholders' equity (deficit):
Current portion of long-term debt
Current portion … of deferred sublicense revenue
Accounts payable, accrued expenses and other current liabilities
Long-term debt, net
Operating lease liabilities, net
8-K
EX-99.1
PHASQ
PhaseBio Pharmaceuticals Inc
12 Aug 22
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8:32am
Other assets
Total assets
Liabilities and stockholders' deficit:
Current portion of long-term debt
Current portion of deferred sublicense revenue …
Accounts payable, accrued expenses and other current liabilities
Long-term debt, net
Operating lease liabilities, net
Long-term portion of deferred
8-K
EX-99.1
PHASQ
PhaseBio Pharmaceuticals Inc
23 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:33am
, and Other 17,839,108 Accrued Interest 140,000 Short Term Operating Lease Liability 501,407 Long Term Portion of JMB Debt - Long Term Operating Lease … Liability 879,227 Long Term Portion of Deferred Sublicense Revenue 7,409,687 Development Derivative 108,828,082 Total Liabilities 172,047,762 Common
8-K
EX-99.1
PHASQ
PhaseBio Pharmaceuticals Inc
10 Nov 21
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
4:35pm
assets
Total assets
Liabilities and stockholders' deficit:
Current portion of long-term debt
Current portion of deferred sublicense revenue
Accounts … payable, accrued expenses and other current liabilities
Long-term debt, net
Operating lease liabilities, net
Deferred sublicense revenue, net
8-K
EX-99.1
u5iegbu2 w3c
11 Aug 20
PhaseBio Reports Recent Business Highlights and Second-Quarter 2020 Financial Results
4:09pm
8-K
EX-99.1
pg26ww ejt0ry53wts1
13 May 21
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
4:06pm
8-K
EX-99.1
ii5f e0opf8
29 Nov 18
PhaseBio Reports Third Quarter 2018 Financial and Business Results
4:41pm
8-K
EX-99.1
e6lry5pb2lqe1v teunl
15 Mar 21
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
8:10am
8-K
EX-99.1
klwczgq
13 Aug 19
PhaseBio Reports Second Quarter 2019 Financial Results and Recent Corporate Progress
4:05pm
8-K
EX-99.1
a43dyx
14 Nov 19
PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress
8:16am
8-K
EX-99.1
to3u bjmbfpeeh4
12 Nov 20
PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results
4:12pm
8-K
EX-99.1
ze1 rlyzuh17
30 Jun 23
Other Events
4:21pm
8-K
EX-99.1
xt68i2n1llkicqm11
12 May 20
PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights
4:08pm
8-K
EX-99.1
y1n90llgldekayv
30 Mar 20
PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights
8:08am
8-K
EX-99.1
ikanyzo
29 Nov 23
Other Events
4:55pm
8-K
EX-99.1
3nkqadfcs nhdwgvrtj
24 Mar 22
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
4:12pm
8-K
EX-99.1
ec8mv047 ct8pjf
26 Mar 19
PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results
4:05pm
8-K
EX-99.1
gs58q3h780chpl1g
9 May 19
PhaseBio Reports First Quarter 2019 Financial and Business Results
4:05pm
8-K
EX-99.1
nnsx1t1xu gul
25 Aug 23
Other Events
12:34pm